pathology of myeloproliferative disease, include JAK-2 (43-57%), CALR (3%) and MPL (3%). Interestingly, it has been hypothesized that MDS with ring sideroblasts (MDS-RS) can transform into MDS/MPN-RS-T with acquisition of the JAK-2 mutation.
MDS/MPN-RS-T include older age (>80), low Hb (<8 g/dl), abnormal cytogenetics, the presence of SETBP-1 or ASXL-1 mutations and the absence of SF3B1 or JAK-2 mutations. 4 It is interesting to compare outcomes and variables between MDS/MPN-RS-T and its sister conditions MDS-RS and essential thrombocythemia (ET). A recent study has shown that survival in MDS/MPN-RS-T significantly exceeds that of MDS-RS (76 months versus 63 months) and compares poorly with survival in ET (115 months). 2 Thrombotic events in MDS/MPN-RS-T and ET were shown to exceed those of MDS-RS, which may be expected considering the disease characteristics. Rates of transformation to AML were similar in the two MDS subtypes but lower in ET, the myeloproliferative counterpart.
This case is noteworthy as MDS/MPN-RS-T has a relatively low transformation rate to AML, with a leukemic transformation rate per 100 years of 1.8 2 . A recent paper described two cases; both were patients who were aged greater than 70 years and had been diagnosed with MDS/MPN-RS-T at least two years prior to transformation. 4 One patient had cytogenetics exhibiting clonal evolution, with 7q deletion detected in the marrow following transformation, and died from neutropenic sepsis with chemotherapy; the second did not have clonal evolution and was undergoing chemotherapy at the time of publication.
Another case report involved a 70-year-old patient who died from AML transformed from MDS/MPN-RS-T; this case involved the development of a monosomy 7 clone in the leukemic marrow. 5 The refractoriness of the transformed AML in our case to multiple lines of chemotherapy also serves to highlight the aggressive nature of the disease.
In summary, we describe a case of MDS/MPN-RS-T with transformation to treatment-refractory AML highlighted by the presence of trisomy 13 and resistant thrombocytosis. Although transient, our patient's relative "response" to oral busulfan was unexpected but does suggest that this therapy may be clinically useful in similar cases. Incidence rates of hemolytic anemia in temporal association with Privigen use in period 1 and period 2, overall and stratified by Privigen indication and dose Recent reports of increased hemolytic anemia rates relate to the change in the IVIG production from Cohn's method (cold-ethanol fractionation), that reduced isoagglutinins, to chromatographic processes with higher purity and functional integrity. 4 One available IVIG product is Privigen (CSL Behring, Bern, Switzerland) that until 2013 was produced with a chromatographic process lacking dedicated steps to reduce isoagglutinins. To reduce the isoagglutinin titers and the risk of hemolytic anemia with Privigen, a two-step approach was implemented: exclusion of donors with high anti-A titer donors introduced in mid-2013, 4 followed by an immunoaffinity chromatography step which started in Oct-2015. 5 We conducted a study to describe the risk of hemolytic anemia before and after the first step of exclusion of high anti-A titers donors from pooled plasma in the manufacturing of the IVIG Privigen. at low dose to 3.41 at high dose, P < .01), was attenuated in period 2 (0.53 to 1.44, P 5 .21).
ORCID
With Privigen administered for immune thrombocytopenia and period 1 as the reference, the adjusted IRR was 0.46 (P 5 .02), and when given at high dose (1.75 g/kg body weight) it was 0.48 (P 5 .03, Table 1 ). The relative risk reduction of 52% resulted in an absolute reduction of 1.55 hemolytic anemia cases avoided per 10 000 persondays of high-dose IVIG treatment in period 2 vs 1.
In summary, using a large hospital-based cohort of over 16 000 patients treated with Privigen we found a decrease in the risk of hemo- This study supports an association between dose of IVIG treatment and risk of hemolytic anemia and indicates that the exclusion of donors with high titers of anti-A from plasma pools was associated with a reduction of risk with high dose therapy.
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